Tocagen Inc., a biopharmaceutical company, announced that Asha Das has been named vice president of clinical development and medical affairs.
Prior to joining Tocagen, she held positions of increasing responsibility at Genentech, including leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.
"Our clinical group now boasts three oncologists, and their perspectives, particularly Asha's insights from her work expanding Avastin into use in recurrent glioblastoma, will be extremely valuable as we transition into late-stage development,” said Jamey Skillings, chief medical officer of Tocagen. “I look forward to working with Asha again, as during our time together at Genentech I was extremely impressed with her depth of expertise and knowledge of the clinical development of oncology therapeutics."
Prior to Genentech, Das was an associate director at Eisai, focused on clinical activities related to the oncology therapeutics HALAVEN and LENVIMA. Previously, she was head of the neuro-oncology program at Cedars-Sinai in Los Angeles.
Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology and was a clinical fellow in neuro-oncology at Massachusetts General Hospital. She completed a residency in neurology at Cornell Medical Center. Das also held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. She obtained her medical degree and bachelor's degree from Cornell University.